The anti-CD19 mAb conjugated to a mayatansine derivative SAR3419, the anti-B cell lactosamine mAb mAref-216 and the anti-CD37 IgG fusion protein TRU-016 may be promising reagents for pediatric B ...
A clinical-stage biotech company developing therapeutics for patients with immune-mediated diseases. The company’s pipeline includes: budoprutug, an anti-CD19 monoclonal antibody that has demonstrated ...
(NEEQ Code: 874070, Mabworks) for rights to develop and commercialize MIL116 (now CLYM116), an anti-APRIL (A PRoliferation-Inducing Ligand) monoclonal antibody ... s anti-CD19 antibody, budoprutug.
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically ...
In terms of [Monjuvi] alone, [Monjuvi] is what we call an anti-CD19 monoclonal antibody. Essentially this drug targets CD19, which is a signal that is found on the surface of many of the cancer cells ...
The study included 548 patients with relapsed or refractory follicular lymphoma. Patients received either a combination of tafasitamab - a humanized Fc-modified cytolytic CD19-targeting monoclonal ...
The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody conjugated with MMAF using the noncleavable MC, which is the same linker–cytotoxic agent ...
The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases ...